New Frontiers in Cell Line Development and Opportunities for Biosimilars

Conference Description

Key Speakers Include:-

Arun Bhatt, President, Clininvent Research 

R. H. Jani, Senior Vice President, Clinical R&D, Cadila

Purnima Sharma, Managing Director, Biotech Consortium India Limited BCIL

Annaswamy Vaidheesh, Vice President- Government affairs Asia Pacific, Johnson & Johnson

Bobby George, Asssitant Vice President and Head, Regulatory Affairs, Reliance Life Sciences

Dilip Pawar, Director and Head Clinical Development, Dr Reddys

Kaustubh Berde, Vice President & Head - International Formulations, Panacea Biotec

Yatin Gokarn, Narotam Sekhsaria Distinguished Professor of Chemical Engineering, Institute of Chemical Technology.

(Former Associate Director, Genentech (San Francisco)

Anurita Majumdar, Director - Medical & Regulatory - India & South Africa, Eli Lilly

Chirag Trivedi, Associate Director - Project Management & Strategic Initiatives, Sanofi-Aventis

Kedar Suvarnapathaki, Head - Regulatory Affair, Boehringer Ingelheim

Yasmin Shenoy, Director-Regulatory Affairs, Sanofi-Aventis

Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates

Plus Many More...

The recent establishment of regulatory guidelines for biosimilars in India is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry. Due to the limited clinical database at the time of approval of a biosimilar, vigorous pharmacovigilance is required. & Biosimilars are set to become an important part of the future medicines market.

To know more about conferences on : 

3rd Biosimilars Congregation 2013